期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗难治性、复发性、多发性骨髓瘤的初步临床研究

下载PDF
导出
作者 陈芾珩 苏永忠 刘元生 庄春兰
机构地区 汕头大学医学院第一附属医院血液科
出处 《实用临床医药杂志》 CAS 2009年第5期55-56,共2页 Journal of Clinical Medicine in Practice
关键词 多发性骨髓瘤 难治/复发性 硼替佐米
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Bross P F, Kane R, Farrell A T, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma[J]. Clin Cancer Res, 2004, 10(15): 3954.
  • 2Blade J, Samson D, Reece D, et al. Criteria forevaluating disease responseand progression in patient swith multiple myeloma t reated by high dose therapy and haemopoietic stem cell t ransplantation. Myeloma Subcommitte for the EBMT[J]. Br J haematol, 1998, 102(5): 1115.
  • 3瞿文,邵宗鸿.蛋白酶体抑制剂硼替佐米治疗血液恶性肿瘤的研究[J].医学综述,2007,13(15):1181-1182. 被引量：2
  • 4Richardson P G, Barlogie B, Berenson N J, et al. A phase 2 study of bortezomib in replased, refractory myeloma[J]. N Engl J, 2003, 348(26): 2609.
  • 5Richardson P G, Sonneveld P, Schuster M W, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma: A phase 3 randomized study (APEX)[J]. N Engl J Med, 2005, 352(24): 2487.
  • 6Terpos E, Anagnostopoulos A, Kastritis E, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: Results of a phase Ⅱ clinical trial[J]. Blood, 2005, 106: 363.

二级参考文献20

  • 1Ling YH,Liebes L,Jiang JD,et al.Mechanisms of proteasome inhibitor PS-341-induced G z-M-phase arrest of apoptosis in human non-small all hung cancerlines[J].Clin Cancer Res,2003,9(3):1145-1154.
  • 2Kisselev AF,Apoian TN,Woo KM,et al.Thesizes of peptides generated from protein by mamalian 26S and 20S proteasome[J].J Biol Chem,1999,274(6):3363-3371.
  • 3Lloda M,Cukor B,Tam S,et al.Iincreased proteasome-dependent degradation of the cyclindependentkinase inhibitor p27 in aggressive colorectal carcinomas[J].Nature Med,1997,3(2):152-154.
  • 4Hengst L,Reed SI.Translational control of p27/kipl accumulation during the cell cycle[J].Science,1996,271(5257):1861-1864.
  • 5Adams J.Development of the proteasome inhibitor ps-341[J].Oncologist,2002,7(1):9-16.
  • 6Wang D,Moriggl R,Stravopodis D,et al.A small amphipathic alpha-hellical region is required for transcriptional activitivities and proteasome dependent tumor of thetyrosine phosphorylated stat 5[J].EMBO J,2000,19(3):392-399.
  • 7Salghetti SE,Muratani M,Wijnen H,et al.Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis[J].Proc Natl Acad Sci USA,2000,97(7):3118-3123.
  • 8Smith N,Rubenstein J,Eggener S,et al.The p53 tumor suppressor gene and nuclear protein:basic science review and relevance to the management of bladder cancer[J].J Uroul,2003,169(4):1219-1228.
  • 9Orlowski R,Baldwin A.NF-κB as a therapeutic target in cancer[J].Trend Mol Med,2002,8(8):385-389.
  • 10Wang C,Deng L,Hong M,et al.TAK1 is a ubiquitin-dependent kinase of MKK and IKK.[J].Nature,2001,412(6844):346-351.

共引文献1

实用临床医药杂志
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部